EA
CHRS icon

Emerald Acquisition’s Coherus Oncology CHRS Stock Holding History

Emerald Acquisition’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.4M Buy
52,111
+37,134
+248% +$1.01M ﹤0.01% 1948
2016
Q2 		$253K Buy
+14,977
New +$281K ﹤0.01% 2678

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Acquisition's CHRS Position: Q3 2016 in Review

Emerald Acquisition increased its Coherus Oncology (CHRS) stake by 248% in Q3 2016, buying an estimated $1.01M and bringing the position to 52,111 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1948.

Emerald Acquisition first reported a position in CHRS in Q2 2016 and has held it in 2 quarters since. 117 funds tracked by Wall St. Rank hold CHRS as of Q3 2016.

  • Emerald Acquisition held 52,111 shares of Coherus Oncology worth $1.4M as of Q3 2016.
  • Emerald Acquisition bought 37,134 Coherus Oncology shares in Q3 2016, an estimated $1.01M.
  • Coherus Oncology made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #1948 holding.
  • Emerald Acquisition first reported a position in Coherus Oncology in Q2 2016 and has held it in 2 quarters since.
  • 117 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.